The results of a large, randomized, North American trial (SWOG S0124) that compared etoposide and cisplatin with irinotecan and cisplatin for patients with extensive small-cell lung cancer have failed to confirm the benefit observed with irinotecan that was demonstrated in an earlier Japan Clinical Oncology Group study (JCOG 9511).
References
Noda, K. et al. Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive small-cell lung cancer. N. Engl. J. Med. 346, 85–91 (2002).
Hanna, N. et al. Randomized phase III trial comparing irinotecan/cisplatin with etoposide/cisplatin in patients with previously untreated extensive-stage disease small-cell lung cancer. J. Clin. Oncol. 24, 2038–2043 (2006).
Lara, P. N., Jr et al. Phase III trial of irinotecan/cisplatin compared with etoposide/cisplatin in extensive-stage small-cell lung cancer: clinical and pharmacogenomic results from SWOG S0124. J. Clin. Oncol. 27, 2530–2535 (2009).
Hermes, A. et al. Irinotecan plus carboplatin versus oral etoposide plus carboplatin in extensive small-cell lung cancer: a randomized phase III trial. J. Clin. Oncol. 26, 4261–4267 (2008).
Schmittel, A. H. Irinotecan plus carboplatin versus etoposide plus carboplatin in extensive disease small cell lung cancer: Results of the German randomized phase III trial [abstract]. ASCO Meeting Abstracts 27, 8029 (2009).
Palomaki, G. E., Bradley, L. A., Douglas, M. P., Kolor, K. & Dotson, W. D. Can UGT1A1 genotyping reduce morbidity and mortality in patients with metastatic colorectal cancer treated with irinotecan? An evidence-based review. Genet. Med. 11, 21–34 (2009).
Gandara, D. R. et al. Japanese-US common-arm analysis of paclitaxel plus carboplatin in advanced non-small-cell lung cancer: a model for assessing population-related pharmacogenomics. J. Clin. Oncol. 27, 3540–3546 (2009).
Glisson, B. S. Recurrent small cell lung cancer: update. Semin. Oncol. 30, 72–78 (2003).
Inoue, A. et al. Randomized phase II trial comparing amrubicin with topotecan in patients with previously treated small-cell lung cancer: North Japan Lung Cancer Study Group Trial 0402. J. Clin. Oncol. 26, 5401–5406 (2008).
Eckardt, J. R. et al. Phase III study of oral compared with intravenous topotecan as second-line therapy in small-cell lung cancer. J. Clin. Oncol. 25, 2086–2092 (2007).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
B. S. Glisson declares the receipt of grant/research support from Pfizer Inc. F. M. Johnson declares no competing interests.
Rights and permissions
About this article
Cite this article
Johnson, F., Glisson, B. Irinotecan or etoposide as front-line therapy for SCLC?. Nat Rev Clin Oncol 6, 562–563 (2009). https://doi.org/10.1038/nrclinonc.2009.141
Issue Date:
DOI: https://doi.org/10.1038/nrclinonc.2009.141
- Springer Nature Limited